Second Quarter 2025
Second quarter 2025 results were reviewed by management during a live audio webcast with the financial community on July 31, 2025. The presentation was followed by a Q&A session.
Featuring
Paul Hudson
Chief Executive Officer
François Roger
Chief Financial Officer
Houman Ashrafian
Head of Research and Development
Highlights
We delivered double-digit sales growth in Q2. Our strategic focus on innovation continues to drive our top line performance, with significant contributions from our nine newly launched medicines and vaccines. With important pipeline milestones anticipated in H2, we look forward to bringing more scientific breakthroughs to patients.
Paul Hudson
Chief Executive Officer